China-Administration of Nicorandil Group（CHANGE）

• Status: Enrolling by invitation
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

We compared the infarct and edema size in ST-segment elevation acute myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) treated by nicorandil before and after the reperfusion with those standard therapy treated by PCI

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital
• Treatments: Nicorandil

Criteria

Inclusion Criteria:

1. Acute ST-T elevation MI patients (<12h)

2. undergoing emergency PCI；

3. Subject has read and signed a written, informed consent form.

Exclusion Criteria:

1. SBP<80mmHg；

2. LM stenosis

3. Aortic dissection；

4. MI (<6 month)

5. PCI或CABG (<6 month)

6. Already under the treatment of Nicorandil；

7. Contraindicated or intolerable to Nicorandil

8. severe adverse effects to CMR or MRI；

9. Currently (or within one month) participating in another new drug trial.；

10. Pregnant or lactation period；

11. Severe somatic disease preventing the participant from completing the trial, or based on the discretion of the investigators, the patient is incapable of participating; Individuals with abnormal laboratory test results and/or clinical manifestations rendering them unsuitable to participate as judged by the investigators;